Cardiotoxicity: Importance of biomarkers
The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant diseases, usually has certain limitations due to its cardiotoxicity (CT) and consequent cardiomyopathy, or even heart failure. CT is defined as any cardiac injury connected with oncology treatment, whether it i...
Main Authors: | Kostadinović Jelena, Popadić Višeslav, Klašnja Slobodan, Klisić Aleksandra, Kotur-Stevuljević Jelena, Andrić Zoran, Zdravković Marija |
---|---|
Format: | Article |
Language: | srp |
Published: |
Pharmaceutical Association of Serbia, Belgrade, Serbia
2023-01-01
|
Series: | Arhiv za farmaciju |
Subjects: | |
Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2023/0004-19632301001K.pdf |
Similar Items
-
Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01) -
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
by: Pooja P. Advani, et al.
Published: (2023-05-01) -
Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01) -
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
by: Belén Díaz‐Antón, et al.
Published: (2022-04-01) -
Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)